The Indian pharmaceutical industry is the second-fastest growing industry sector in the country.So when, Japanese drug firm Daiichi Sankyo on June 11 announced the acquisition of a majority stake of more than 50 per cent in domestic major Ranbaxy for over Rs 15,000 crore (Rs 150 billion), marking the largest ever deal in Indian pharma industry, it stunned the industry. It has shown a revenue growth of 27.32 per cent (as per the latest data available) to touch Rs 25,196.48 crore (Rs 251.96 billion) in 2006-07. The industry also saw Indian drug companies buying out many small firms the world over as they expand their reach, markets and muscle.
Ranbaxy is India's largest pharmaceutical company with a 2007 turnover of Rs 4,198.96 crore (Rs 41.989 billion) by sales. The deal will create the 15th biggest drugmaker globally.
Daiichi would also make an open offer for an additional 20 per cent stake in Ranbaxy at a price of Rs 737 per share. This deal values Ranbaxy at about $8.5 billion. Malvinder Singh will continue as CEO and MD of the Ranbaxy, post deal too.
to find out what this deal means for the investor, the company and the buyer; and also to find out which are the other top 9 pharma companies in India?
#2. Dr Reddy’s Laboratories
Dr Reddy’s Labs, with a 2007 turnover of Rs 4,162.25 crore (Rs 41.622 billion), is India’s second largest drug firm by sales.
#3. Cipla
Pharma major Cipla is India’s third largest pharmaceutical firm. Its 2007 revenues stood at Rs 3,763.72 crore (Rs 37.637 billion).
#4. Sun Pharma Industries
The Dilip Sanghvi-led Sun Pharma is the nation’s 4th largest pharma company at a 2007 revenue Rs 2,463.59 crore (Rs 24.635 billion).
#5. Lupin Labs
Lupin Labs is India’s 5th largest drugs firm. Its 2007 revenue was at Rs 2,215.52 crore (Rs 22.155 billion).
Aurobindo is India’s 6th largest pharma firm by sales. Its 2007 revenues stood at Rs 2,080.19 crore (Rs 20.801 billion).
#7. GlaxoSmithKline Pharma
GSK is India’s 7th largest drug company with a turnover of Rs 1,773.41 crore (Rs 17.734 billion) for 2007
#8. Cadila Healthcare
Cadila’s 2007 revenue was Rs 1,613.00 crore (Rs 16.13 billion), which makes it India’s 8th largest pharma firm.
#9. Aventis Pharma
Aventis Pharma, with a 2007 revenue of Rs 983.80 crore (Rs 9.838 billion) is the 9th largest Indian drug company.
#10. Ipca Laboratories
At a revenue of Rs 980.44 crore (Rs 9.804 billion), Ipca is India’s 10th largest pharma firm by sales.
Cipla Laboratories continues to be the largest pharmaceutical company in the domestic market.
Cipla has topped the ORG-IMS rankings for the month of November with a market share of 5.42 per cent and sales of Rs 146.32 crore (Rs 1.463 million), edging out Ranbaxy [ Get Quote ] which stood at second position with 5.09 per cent market share and Rs 137.49 crore (Rs 1.374 million) sales.
In October, Cipla topped with Rs 152.04 crore (Rs 1.520 billion) sales and a market share of 5.23 per cent, ahead of Ranbaxy, which garnered Rs 148.40 crore (Rs 1.484 million) sales and 5.11 per cent market share, said sources.
Cipla overtook Ranbaxy and GlaxoSmithKline [ Get Quote ] India to become the largest pharmaceutical company in the domestic market for the first time in May 2007.
| India's Top 7 Drug Cos | |
| Rank | Company |
| 1 | Cipla |
| 2 | Ranbaxy |
| 3 | GlaxoSmithKline |
| 4 | Zydus Cadila |
| 5 | Alkem Laboratories |
| 6 | Sun Pharma [ Get Quote ] |
| 7 | Taj Pharmaceuticals Ltd. |
While GSK [ Get Quote ] has maintained its number three position in November, Zydus Cadila (fourth), Alkem Laboratories (fifth) and Sun Pharma (sixth) have moved one rank up from October.
Nicholas Piramal, which faced raw material shortages for its largest selling codiene based formulations, like Phensydyl, in recent months, slipped three positions to number seven in November.
ORG-IMS, the largest market intelligence company in India focusing on the healthcare sector, tracks sales of Indian pharmas on a monthly basis, through over 3,000 stockists and 6,000 doctors.
"Indian companies are increasing their share in the domestic market mainly due to increased number of high value new introductions, though the number of new introductions have reduced recently," Shailesh Gadre, managing director, ORG-IMS, said in an interview last week.
Ranbaxy's growth has been largely driven by new introductions such as Volix, an anti-diabetes drug launched in January, Oframax-Forte and anti-asthmatic drug Synasma, which it in-licensed from Eurodrug Laboratories.
Ranbaxy's antibiotic Mox (amoxyllin), which was not among the top ten brands a year ago, has grown to become the fourth largest brand in the domestic market with monthly sales at Rs 9.8 crore (Rs 98 million) in November, sources said.
Cipla's growth was powered by positive growth in their existing portfolio, especially its respiratory products.
However, GSK has lost market share mainly in its main portfolios such as anti- infectives, dermatologicals and pain management drugs which grew slower than the market for these products, ORG-IMS said.
ORG-IMS named Alkem Laboratories as the only company among the top ten for which both older products (10 per cent) and new introductions (12 per cent) have contributed significantly to value growth.
"Our growth in the domestic market is mainly due to the growth of our anti-infective Taxim and other brands such as Taximo, Clavem, A to Z and Gemcal," explained Vinod Dua, head, domestic business of Alkem Laboratories.
Alkem's Taxim is now the third largest brand in the domestic market with sales of Rs 10.3 crore (Rs 103 million), behind Pfizer's [ Get Quote ] cough syrup Corex (Rs 15.2 crore (Rs 152 million)) and Novartis India's [ Get Quote ] pain killer Voveron (Rs 11.6 crore -- Rs 116 million).
The leading players in the Indian pharmaceutical market comprise both India-based and MNCs. This report provides an insight to the current state of Indian pharmaceutical industry as well as the evolving trends. This report analyzes the Indian pharmaceutical industry in light of market size, key drivers and resistors, trends and competitive positioning in the global market. It also analyzes the competitive landscape of the industry based on financial and operational (field force strength, R&D spend, exposure to chronic therapeutic areas and the US pharmaceutical market) parameters.
This report also compares and analyzes the competitive positioning of Indian pharmaceutical market in the context of global pharmaceutical market. The report also includes profiles of the top ten companies in the industry and also involves a brief summary of top 11 to 20 players.
The top 10 companies in the Indian pharmaceutical industry were assessed on following parameters:
• market share in the Indian pharmaceutical market;
• marketed products and therapeutic focus;
• growth strategies and major acquisitions and divestments in this market;
• key partnerships and alliances formed by these companies;
• business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
Key findings
The Indian pharmaceutical market was valued at $7,743m in 2008, an increase of 4.0% over 2007. Business Insights anticipates that Indian pharmaceutical market will grow at a faster pace than the global pharmaceutical market, approximately at a CAGR of 13.2% during 2009–14 to reach a total value of $15,490m in 2014.
India has emerged as a key destination for global pharmaceutical companies due to its high growth prospects led by ageing population, changing disease profile, and improving patent regime and socio-economic conditions.
The Indian pharmaceutical market is highly competitive and fragmented with the top 10 players accounting for 36.1% of the total R&H sales in 2008.
India started to comply with World Trade Organization’
Use this report to
• Learn from the strategies of the Indian pharmaceutical companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.
• Benchmark your performance against the leading Indian pharmaceutical companies using market share data by company and comprehending their strategies.
• Understand the major issues affecting the Indian pharmaceutical market.
• Predict the key growth areas in the Indian pharmaceuticals market arising from the change in the lifestyle of consumers and strengthening of the IPR regime in India.
• Save time, money and resources on analyzing the performance of the key Indian pharmaceutical companies using this report.
Key issues
Inadequacies in the new patent regime: Provisions related to Sec 3(d) of the Patent (Amendment) Act 2005 prevent ever-greening of drug patents as it does not allow patenting new uses of an existing drug. In addition, compulsory licensing allows Indian players to continue manufacturing generics of patented products for export to underdeveloped countries.
Lack of infrastructure:
Limited funds: Limited funding from FIs, venture capitalists and the government may slowdown the development of biotechnology industry in India.
Regulatory hurdles: Increasing due diligence and compliance with standards leads to cost overrunning and delay in new product launches.
Intense competition:
Discover
• What was the market size of the Indian pharmaceutical market in 2008?
• What will be the market size of the Indian pharmaceutical market during 2009-14?
• What are the trends in the Indian pharmaceutical market?
• Who are the top 20 players in the market?
• What is the market share of each of the top 10 companies?
• What are the growth strategies of the top 10 companies?
• What are the strengths of the top 10 players in the Indian pharmaceutical market?
• What are the growth opportunities for the global top 10 Indian pharmaceutical companies?
• What is the most contentious issue facing the Indian pharmaceutical market?
# # #
Aarkstore Enterprise specializes in providing business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
European Quality Systems  | |||||||||||
| |||||||||||
 | |||||||||||
Business today face far more competition and external influences then they did five to 10 years ago. Competing in today's global economy can be tough for the small to midsize business (SMB). Smaller organization faces the same market pressure as the Global 2000. They are challenged by the need the customer and compliance mandates, manage supplier effectively, control Costs, and gain new customers to grow the business.
For the majority of firms in this industry, the actual manufacture of drugs is the last stage in a lengthy process that begins with scientific research to discover new products and to improve or modify existing ones. The R&D departments in pharmaceutical and medicine manufacturing firms start this process by seeking and rapidly testing libraries of thousands to millions of new chemical compounds with the potential to prevent, combat, or alleviate symptoms of diseases or other health problems. Scientists use sophisticated techniques, including computer simulation, combinatorial chemistry, and high-through-put screening, to hasten and simplify the discovery of potentially useful new compounds.
New Developed Products:
Tyramine, Benzene, Benzyl methyl ketone, 3'-Aminoacetophenone, 3'-Chloroacetophenone, Piperidine and its salts, Dutasteride, Fluconazole, Norfloxacin
Product | Therapeutic Category | Documentation / Specifications | CAS No. |
|---|---|---|---|
| Anti-viral drug | INN | [ 204255-11-8 ] | |
| Cough and Cold | BP / USP | [ 154-41-6 ] | |
| Cough and Cold | DMF, Cos | [ 20368-45-0 ] | |
| Etafedrine | Cough and Cold | DMF | [ 530-35-8 ] |
| Tramadol | Pain Management | TIP | [ 36282-47-0 ] |
| Methylphenidate | CNS | DMF | [ 113-45-1 ] |
| Morphine HCl | Analgesic | BP / EP | [52-26-6] |
| Morphine sulphate | Narcotic analgesic | BP / EP / USP | [64-31-3] |
| Ephedrine (EPH) | Cough and Cold | USP | [ 50-98-6 ] |
| Pseudoephedrine hydrochloride | Decongestant | INN | [ 90-82-4 ] |
| Codeine base | Analgesic,Antitussive | BP / EP / USP | [76-57-3] |
| Codeine phosphate hemihydrate | Analgesic,Antitussive | BP / EP / USP | [41444-62-6] |
| Zolpidem Tartrate | Hypnotic | BP / EP | [99294-93-6] |
Pharmaceuticals API List
Oseltamivir Phosphate  |
| Cefdinir |
| Ibuprofen |
*** Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute as an offer for sale in territories where it is not permitted by law.
| The Chemicals business sector focuses on high-quality chemical products for technically demanding applications in R&D and industry. Many years of experience and innovative product solutions make us a preferred partner for laboratories and production. Let us take you on a journey into our world of research to discover new approaches that could prove useful in your work. In regular intervals we'll be introducing you to interesting topics, this week "On the way to a bright future"
| ||||||||||||||||
 Phenyl acetic acid, its esters, and its salts | [ CAS NO.103-82-2 ] | |||||||||||||||
| | 3,4-methylenedioxyphenyl-2-propanone | [ CAS NO.4676-39-5 ] | ||||||||||||||
| Pseudoephedrine, its salts, optical isomers, and salts of optical isomers | [ CAS NO.90-82-4 ] | |||||||||||||||
| | Piperidine and its salts | [ CAS NO.110-89-4 ] | ||||||||||||||
| Methylamine | [ CAS NO. 74-89-5 ] | |||||||||||||||
| | Propionic anhydride | [ CAS NO.123-62-6 ] | ||||||||||||||
| Para Methoxy Phenyl Acetone | [ CAS NO.122-84-9 ] | |||||||||||||||
| | Para Methoxy Phenyl Acetic Acid | [ CAS NO.104-01-8 ] | ||||||||||||||
| Raspberry Ketone | [ CAS NO.5471-51-2 ] | |||||||||||||||
| | Benzyl Acetone | [ CAS NO.2550-26-7 ] | ||||||||||||||
| Tyramine | [ CAS NO.51-67-2 ] | |||||||||||||||
| | Biphenyl (Phenyl benzene) | [ CAS NO.92-52-4 ] | ||||||||||||||
| 1-phenyl-1-hexanone | [ CAS NO.942-92-7 ] | |||||||||||||||
| | Benzene | [ CAS NO.71-43-2 ] | ||||||||||||||
| Benzyl methyl ketone | [ CAS NO.103-79-7] | |||||||||||||||
| | Bromo phenyl acetone (1-Bromo-1-phenyl-2-propanone) | [ CAS NO.23022-83-5 ] | ||||||||||||||
| 3'-Aminoacetophenone | [ CAS NO. 99-03-6 ] | |||||||||||||||
| | 3'-Chloroacetophenone | [ CAS NO. 99-02-5 ] | ||||||||||||||
| * **The following chemicals or the salt, optical isomer, or salt of an optical isomer of the following chemicals o Ethylamine o Propionic anhydride o Isosafrole o Safrole o Piperonal o N-methylephedrine o N-methylpseudoephedrine o Acetic anhydride o Acetone o Benzyl chloride o Diethyl ether o Potassium permanganate o 2-butanone (or methyl ethyl ketone) o Toluene o Hydrochloric acid (including anhydrous hydrogen chloride) o Methyl isobutyl ketone | ||||||||||||||||
 | ||||||||||||
| ||||||||||||
